Technical Trend Overview and Price Movement
On 4 Aug 2026, Astrazeneca Pharma India Ltd closed at ₹8,296, up from the previous close of ₹8,103.65, marking a daily gain of 2.37%. The intraday range was ₹8,171.30 to ₹8,497.70, reflecting heightened volatility. The stock remains below its 52-week high of ₹9,850 but comfortably above its 52-week low of ₹7,630. This price action coincides with a technical trend shift from bearish to mildly bearish, signalling a tentative improvement in momentum but not yet a full bullish reversal.
MACD and Momentum Indicators
The Moving Average Convergence Divergence (MACD) indicator remains bearish on the weekly timeframe, indicating that the short-term momentum is still under pressure. However, the monthly MACD has improved to mildly bearish, suggesting that longer-term selling pressure is easing. This divergence between weekly and monthly MACD readings highlights a transitional phase where short-term bears retain control but longer-term momentum is stabilising.
RSI and Overbought/Oversold Conditions
The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, hovering in a neutral zone. This absence of extreme overbought or oversold conditions implies that the stock is neither strongly overextended nor deeply undervalued technically. Investors should watch for any RSI breakouts above 70 or dips below 30 to identify potential momentum shifts.
Moving Averages and Bollinger Bands
Daily moving averages present a mildly bearish stance, with the stock price slightly below key averages, indicating resistance to upward momentum in the short term. Conversely, Bollinger Bands on the weekly chart are bullish, reflecting recent price strength and increased volatility. The monthly Bollinger Bands, however, remain mildly bearish, reinforcing the notion of a cautious medium-term outlook.
KST and Dow Theory Signals
The Know Sure Thing (KST) oscillator aligns with the MACD, showing bearish momentum on the weekly scale and mildly bearish on the monthly. Dow Theory analysis offers a nuanced view: weekly signals are mildly bullish, hinting at potential accumulation phases, while monthly signals remain mildly bearish, underscoring the need for confirmation before a sustained uptrend can be declared.
Volume and On-Balance Volume (OBV)
On-Balance Volume (OBV) indicators on both weekly and monthly charts show no discernible trend, suggesting that volume is not currently confirming price moves. This lack of volume confirmation may limit the strength of any price advances and warrants caution among traders relying on volume-based momentum.
Comparative Returns and Market Context
When compared to the Sensex, Astrazeneca Pharma India Ltd’s returns reveal a mixed performance. Over the past week, the stock gained 1.57% versus the Sensex’s 2.35%. Over one month, the stock was essentially flat (-0.02%) while the Sensex rose 1.13%. Year-to-date, Astrazeneca Pharma India Ltd has declined 7.93%, slightly underperforming the Sensex’s 7.72% fall. Over one year, the stock’s loss of 6.71% is notably worse than the Sensex’s 2.43% decline.
However, Astrazeneca Pharma India Ltd’s long-term returns are impressive, with a 3-year gain of 118.79% compared to the Sensex’s 20.54%, a 5-year gain of 145.77% versus 46.11%, and a remarkable 10-year return of 714.05% against the Sensex’s 183.92%. These figures highlight the company’s strong growth trajectory over the long haul despite recent volatility.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
Mojo Score and Rating Changes
Astrazeneca Pharma India Ltd currently holds a Mojo Score of 42.0, categorised as a Sell rating. This represents a downgrade from a previous Hold rating as of 2 Jan 2026. The downgrade reflects the deteriorating technical parameters and cautious outlook from MarketsMOJO’s comprehensive evaluation. The company is classified as a small-cap within the Pharmaceuticals & Biotechnology sector, which often entails higher volatility and sensitivity to sector-specific developments.
Implications for Investors and Traders
The mixed technical signals suggest that investors should exercise prudence. While the weekly bullish Bollinger Bands and mildly bullish Dow Theory weekly signals hint at potential short-term strength, the prevailing bearish MACD and KST indicators on weekly charts, combined with mildly bearish monthly trends, indicate that the stock is not yet out of the woods. The absence of volume confirmation further tempers enthusiasm for aggressive buying.
Traders may consider monitoring key technical levels, such as the 52-week high of ₹9,850 and the recent support near ₹7,630, to gauge breakout or breakdown scenarios. The neutral RSI readings imply that momentum could swing in either direction depending on upcoming market catalysts or sector news.
Sector and Industry Context
Within the Pharmaceuticals & Biotechnology sector, Astrazeneca Pharma India Ltd faces competitive pressures and regulatory challenges that can influence technical momentum. The sector’s overall health and investor sentiment towards biotech innovation and pharmaceutical pipelines will be critical in shaping the stock’s trajectory. Given the company’s small-cap status, it is more susceptible to market swings compared to larger peers.
Astrazeneca Pharma India Ltd or something better? Our SwitchER feature analyzes this small-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Conclusion: A Cautious Outlook Amid Transition
Astrazeneca Pharma India Ltd’s recent technical parameter changes reflect a stock in transition. While the shift from bearish to mildly bearish technical trends offers a glimmer of hope, the overall mixed signals from MACD, RSI, moving averages, and volume indicators counsel caution. The downgrade to a Sell rating by MarketsMOJO underscores the need for investors to carefully weigh risks against Astrazeneca’s long-term growth potential.
For those considering exposure to this small-cap pharmaceutical, it is advisable to monitor technical developments closely and remain alert to sector dynamics. The stock’s impressive long-term returns demonstrate its capacity for significant appreciation, but near-term momentum remains fragile and uncertain.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
